RNA, U2 small nuclear 6, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-6P profile across patient tissues and cancer cell-line models. RNU2-6P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, RNU2-6P is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, RNU2-6P RNA expression shows 12,621 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ESCA, COAD, and DLBC as cancer lineages where RNU2-6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-6P survival associations across molecular data types. RNU2-6P RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-6P RNA expression–survival associations across cancer types. High RNU2-6P expression shows unfavorable associations in LUSC, LGG, UVM and CESC, but favorable associations in ESCA and COAD. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify ESCA as the clearest survival context for RNU2-6P RNA expression.
This table summarizes RNU2-6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-6P shows lower tumor expression in THCA and LUAD and higher tumor expression in COAD and KIRC. The COAD box plot shows higher RNU2-6P RNA expression in tumor versus normal tissue (log2 FC = +0.797, t-test p < 0.001).
This table shows molecular features associated with RNU2-6P in patient tissues and cancer cell lines. In patient samples, RNU2-6P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
